KRAS inhibitor Image: Sanofi
Sanofi Considers Acquisition of Mirati Amid Intensifying KRAS Cancer Drug Battle, Reports Bloomberg
Anika Sharma
Mirati Therapeutics experienced a significant surge in its stock price on Thursday, triggered by swirling rumors of a potential acquisition ...
